Blog

The Medicare Loophole Bill: Victories & Next Steps

The Removing Barriers to Colorectal Cancer Screening Act – also known as the “Medicare loophole” bill – is one of Fight CRC’s top legislative priorities. We’ve been working on it for a long time. We know many of you may be getting frustrated that we…

Read Full Post

FDA Approves Entrectinib (ROZLYTREK)

UPDATE: On August 15th, 2019 the Federal Drug Administration approved the drug entrectinib for the treatment of adult and pediatric patients with NTRK fusion-positive, locally advanced or metastatic solid tumors who have either progressed following prior therapies or as initial therapy when there are no…

Read Full Post

Cancer? We’ve Got Mountains to Climb

Fight CRC Ambassador Marijana Kotlaja’s father was diagnosed with stage III colon cancer in October 2018. Her father’s diagnosis quickly changed their family’s lives, habits, and perspectives. Marijana’s father had no family history and their family was unaware of the disease until it became their…

Read Full Post

Grant Reviews: Insights from an expert research advocate

Fight Colorectal Cancer (Fight CRC) research advocates are the most credible patient voice at the research table. Research advocates devote hours upon hours to online and in-person training to educate themselves on the entire colorectal cancer continuum, from prevention to survivorship. They are also passionate…

Read Full Post
Yin Cao Headshot

Yin Cao shares research on a common risk factor for EAO CRC

Yin Cao, a cancer epidemiologist at Washington University School of Medicine in St. Louis, discusses her research investigating sedentary behavior, primarily time spent watching TV, as a risk factor for developing EAO CRC among 18,000 women in the Nurse’s Health Study II. Exercise can have protective…

Read Full Post

Fight CRC published for work in young adult colorectal cancer

Fight Colorectal Cancer (Fight CRC) is excited to announce that the manuscript titled “A summary of the Fight Colorectal Cancer working meeting: exploring risk factors and etiology of sporadic early-age onset colorectal cancer” has been published in the August edition of Gastroenterology. Over 45 experts…

Read Full Post

FDA Approves Biosimilar to Treat Cancer

On June 28, 2019, the FDA approved another biosimilar for bevacizumab (Avastin), called Zirabev (bevacizumab-bvxr) for five different cancer types including: Metastatic colorectal cancer Unresectable, locally advanced, recurrent, or metastatic non squamous non-small cell lung cancer (NSCLC) Recurrent glioblastoma Metastatic renal cell carcinoma, and Persistent,…

Read Full Post

Comments to USPSTF On Screening

UPDATE: In May 2019, the Final Research Plan for Colorectal Cancer: Screening was made available to the public on the USPSTF website. Why is this a big deal? The results could lead to a guideline update, for example, moving the age of screening for average-risk…

Read Full Post